Trials / Not Yet Recruiting
Not Yet RecruitingNCT07226206
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPK-8011QQ | Participants will receive IV SPK-8011QQ |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2031-07-31
- Completion
- 2031-07-31
- First posted
- 2025-11-10
- Last updated
- 2026-03-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07226206. Inclusion in this directory is not an endorsement.